Publication:
The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)

dc.contributor.authorsTanriverdi, Ozgur; Kaytan-Saglam, Esra; Ulger, Sukran; Bayoglu, Ibrahim Vedat; Turker, Ibrahim; Ozturk-Topcu, Turkan; Cokmert, Suna; Turhal, Serdar; Oktay, Esin; Karabulut, Bulent; Kilic, Diclehan; Kucukzeybek, Yuksel; Oksuzoglu, Berna; Meydan, Nezih; Kaya, Vildan; Akman, Tulay; Ibis, Kamuran; Saynak, Mert; Sen, Cenk Ahmet; Uysal-Sonmez, Ozlem; Pilanci, Kezban Nur; Demir, Gokhan; Saglam, Sezer; Kocar, Muharrem; Menekse, Serkan; Goksel, Gamze; Yapar-Taskoylu, Burcu; Yaren, Arzu; Uyeturk, Ummugul; Avci, Nilufer; Denizli, Bengu; Ilis-Temiz, Esra
dc.date.accessioned2022-03-13T12:46:57Z
dc.date.accessioned2026-01-11T15:27:07Z
dc.date.available2022-03-13T12:46:57Z
dc.date.issued2014
dc.description.abstractBrain metastasis in colorectal cancer is highly rare. In the present study, we aimed to determine the frequency of brain metastasis in colorectal cancer patients and to establish prognostic characteristics of colorectal cancer patients with brain metastasis. In this cross-sectional study, the medical files of colorectal cancer patients with brain metastases who were definitely diagnosed by histopathologically were retrospectively reviewed. Brain metastasis was detected in 2.7 % (n = 133) of 4,864 colorectal cancer patients. The majority of cases were male (53 %), older than 65 years (59 %), with rectum cancer (56 %), a poorly differentiated tumor (70 %); had adenocarcinoma histology (97 %), and metachronous metastasis (86 %); received chemotherapy at least once for metastatic disease before brain metastasis developed (72 %), had progression with lung metastasis before (51 %), and 26 % (n = 31) of patients with extracranial disease at time the diagnosis of brain metastasis had both lung and bone metastases. The mean follow-up duration was 51 months (range 5-92), and the mean survival was 25.8 months (95 % CI 20.4-29.3). Overall survival rates were 81 % in the first year, 42.3 % in the third year, and 15.7 % in the fifth year. In multiple variable analysis, the most important independent risk factor for overall survival was determined as the presence of lung metastasis (HR 1.43, 95 % CI 1.27-4.14; P = 0.012). Brain metastasis develops late in the period of colorectal cancer and prognosis in these patients is poor. However, early screening of brain metastases in patients with lung metastasis may improve survival outcomes with new treatment modalities.
dc.identifier.doi10.1007/s12032-014-0152-z
dc.identifier.eissn1559-131X
dc.identifier.issn1357-0560
dc.identifier.pubmed25108599
dc.identifier.urihttps://hdl.handle.net/11424/238004
dc.identifier.wosWOS:000341835700025
dc.language.isoeng
dc.publisherHUMANA PRESS INC
dc.relation.ispartofMEDICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectColorectal cancer
dc.subjectBrain metastasis
dc.subjectPrognosis
dc.subjectPARTITIONING ANALYSIS RPA
dc.subjectPROGNOSTIC-FACTORS
dc.subjectCARCINOMA
dc.subjectSURVIVAL
dc.subjectRADIOSURGERY
dc.titleThe clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)
dc.typearticle
dspace.entity.typePublication
oaire.citation.issue9
oaire.citation.titleMEDICAL ONCOLOGY
oaire.citation.volume31

Files